At least one aspect of 2020 will be the same as any other year – pharma companies will end it with the traditional major data dump at the American Society of He 26 November 2020
At the annual meeting of the American Society of Hematology (ASH), French drugmaker Sanofi has presented positive data for ex-Bioverativ asset sutimlimab. 11 December 2019
At the 2019 ASH annual meeting, Bristol-Myers Squibb has announced positive results from the QUAZAR AML-001 study of an experimental oral hypomethylating agent, 10 December 2019
US pharma major Bristol-Myers Squibb announced over the weekend that its Phase I study of lisocabtagene maraleucel (liso-cel) met its primary and secondary endp 9 December 2019
US biotech bluebird bio has presented new data from its Phase I/II HGB-206 study of its LentiGlobin gene therapy for sickle cell disease (SCD) at ASH. 9 December 2019
Genomic medicine company Sangamo Therapeutics and its pharma partner Pfizer have announced updated follow-up results from the Phase I/II Alta study on the SB-52 9 December 2019
British pharma major AstraZeneca has presented interim Phase III data from the ELEVATE TN study of Calquence (acalabrutinib), at the 2019 American Society of He 9 December 2019
At this year’s annual meeting of the American Society of Hematology (ASH), Johnson & Johnson has impressed with the first clinical data from its anti-BCMA CAR-T 9 December 2019
Swedish Orphan Biovitrum (STO: SOBI) and Novimmune have presented positive data from a pivotal Phase II/III study of Gamifant (emapalumab-lzsg) at the annual me 5 December 2018
Janssen Pharmaceutical, the pharma business of US healthcare company Johnson & Johnson has announced positive Phase III data for Darzalex (daratumumab) at the a 5 December 2018
Swiss pharma giant Roche has presented data from the largest pivotal study to date on children with hemophilia A at the American Society of Hematology Annual Me 4 December 2018
Basel, Switzerland-based Roche has announced new Phase III data for Venclyxto (venetoclax) at the annual meeting of the American Society of Hematology. 4 December 2018
AstraZeneca and its hematology subsidiary Acerta Pharma have presented new, long-term follow-up results for Calquence (acalabrutinib) at the annual meeting of t 4 December 2018
Takeda Pharmaceutical has presented positive results from the Phase III TOURMALINE-MM3 study of Ninlaro (ixazomib) at the annual meeting of the American Society 3 December 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.